Oragenics, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2012; filed May 15, 2012. Oragenics is a development-stage nutraceutical and biotechnology company focused on oral-health probiotics and other technology and drug candidates. It reported limited product and grant revenue and recurring operating losses.
Key financial results
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue, net | $380,527 | $349,937 |
| Cost of sales | $198,209 | $94,977 |
| Gross profit / margin | $182,318 / 47.9% | $254,960 / 72.9% |
| Research and development | $353,198 | $412,901 |
| Selling, general and administrative | $1,307,994 | $1,357,446 |
| Operating loss | $(1,478,874) | $(1,515,387) |
| Net loss | $(1,616,908) | $(1,559,013) |
| Net loss per share | $(0.25) | $(0.275) |
| Cash used in operating activities | $(1,143,100) | $(1,123,621) |
At March 31, 2012, cash and cash equivalents were $967,944, restricted cash $294,104, current assets $1,812,199, and total assets $1,941,320. Working capital was $330,530, compared with a deficit of $8,328,004 at December 31, 2011. Accumulated deficit was $42,612,824. The filing reports no investing cash flow in either quarter.
Material changes and financing
- Revenue increased about 9%; management attributed the increase in ProBiora3 sales principally to an international customer. The filing’s MD&A gives Q1 2011 revenue as $349,947, while the financial statements report $349,937.
- Cost of sales more than doubled, primarily due to costs associated with the international sale, reducing gross margin to 47.9% from 72.9%.
- Operating expenses declined about 6%. R&D fell 14.5%; SG&A fell 3.6%, including lower advertising and marketing following withdrawal from mass retail, partly offset by higher stock-option expense, legal and professional fees, and consulting costs.
- Net loss worsened despite a lower operating loss, primarily because interest expense rose by about $94,500.
- On March 23, the company exchanged $8,737,011 of shareholder debt and accrued interest for 6,285,619 common shares and warrants for 1,571,405 shares. This eliminated the prior revolving credit facility but materially diluted shareholders.
- A new secured loan agreement with its largest shareholder, the Koski Family Limited Partnership (KFLP), provided up to $2.5 million in two $1.25 million advances. The first advance was funded in March; the second was received April 23, after quarter-end. The loan bears 5% interest, matures in three years, is secured by selected technology-related assets, and may automatically convert upon a qualifying $5 million equity financing. The lender also received warrants for 599,520 shares at $2.00 per share.
- Short-term notes payable were $71,578 at quarter-end; the balance sheet also reported a $773,904 shareholder note payable. The filing describes the new loan’s first $1.25 million advance but does not present its face amount as the balance-sheet carrying amount.
Outlook, risks, and other notable matters
- Management said available resources, the KFLP loan and expected grant funds would support the business plan only through June 2012. The company said it needed additional capital, and its financial statements identify substantial doubt about its ability to continue as a going concern.
- Management planned to prioritize the oral probiotic business, while reducing spending on non-probiotic programs until they can be partnered or licensed. It expected continued losses and substantial development expenditures; no quantitative revenue or earnings guidance was provided.
- Development programs include SMaRT Replacement Therapy, for which a Phase 1 trial was underway and expected to conclude in the second half of 2012; MU1140-S, for which preclinical testing was planned in 2012 subject to available capital; and LPT3-04, being positioned for licensing after a proof-of-concept human trial. Management noted some candidates might not be commercially available before 2013.
- An exclusive three-year Japanese distribution contract for oral probiotic products was announced April 10, 2012, with distribution expected to commence in September. The company also announced a dental-channel agreement in February.
- Key risks include inability to raise capital, continued losses and cash burn, dependence on the KFLP, dilution from future financing and outstanding warrants/options, and the possibility that default on secured borrowing could put material technology assets at risk.
- Disclosure controls and procedures were assessed as ineffective because previously identified material weaknesses remained: limited control documentation, insufficient personnel for segregation of duties, and lack of formal accounting and reporting policies. No material legal proceedings were reported.
Important facts for investors to verify
- Current cash runway, actual cash burn, and whether financing beyond the April 2012 loan advance was secured; the stated operating plan was funded only through June 2012.
- The terms, carrying value, collateral and conversion provisions of the KFLP loan, and any subsequent amendments or repayments.
- The share count and potential dilution from the debt exchange and all outstanding warrants and options; the filing reports 12,174,795 shares outstanding as of May 1, 2012.
- Whether revenue growth is repeatable and how product returns, deferred revenue and customer concentration affect reported sales.
- Progress against clinical and preclinical timelines, partnering plans, and remediation of material weaknesses in financial controls.